Over 100M Procedures Performed with Nanosonics’ trophon Devices Across North America Since 2011 Protecting Patients from Ultrasound Probe Cross-Contamination
08 Juni 2022 - 3:02PM
Business Wire
Company Celebrates Over 25,000 installed
trophon devices milestone
Nanosonics (ASX: NAN), a leader in infection prevention
solutions, today announced that patients in North America have been
protected from the risk of ultrasound probe cross-contamination in
over 100 million trophon® high level disinfection (HLD)
procedures.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220608005044/en/
“Our trophon* technology has become the standard of care in
North America for ultrasound probe infection control, evidenced by
over 25,000 installations and partnerships with more than 5,000
health care facilities who trust us for their infection
prevention,” said Ken Shaw, President of the Americas for
Nanosonics. “To date, more than 100 million trophon procedures have
been performed in North America, and we believe this number will
grow substantially, as there are still millions of procedures
performed without the protection of trophon technology. Use of
trophon HLD is fast gaining adoption globally due to data
demonstrating its efficacy and real-life experience protecting more
than 82,000 patients daily from risks of ultrasound probe
cross-contamination.”
The environment is also a beneficiary of trophon technology, as
the by-products of each disinfection cycle are environmentally
friendly oxygen and water. The trophon device may prevent the
disposal of thousands of gallons of water and soaking chemicals
into the environment each year compared to traditional
decontamination methods.
“While there have been great strides in ultrasound infection
prevention, there is still a significant amount of work to do in
terms of widespread adoption of appropriate ultrasound cleaning and
disinfection practices. Planning and implementation of infection
prevention strategies serve to effectively break the chain of
pathogen transmission and, ultimately, infection associated with
use of a reusable medical device,” said Ruth Carrico, Ph.D.,
Executive Director, Norton Infectious Diseases Institute.
“Studies demonstrate ultrasound probes can be contaminated
following patient use,1,2 and almost 50% of ultrasound probes in
both emergency and ICU settings can be contaminated even when they
appear visibly clean,”3 continued Dr. Carrico. “Moreover, after low
level disinfection, ultrasound probes can be contaminated with
virus and bacteria, including human papillomavirus and Chlamydia
Trachomatis, which may then be transmitted to a subsequent
patient.1,4,5 These situations exemplify the critical need for
proper ultrasound infection prevention to ensure safe and
exceptional patient care and protection.”
The trophon device helps reduce the risk of ultrasound
probe-related cross-infection, offering effective bactericidal,
fungicidal, virucidal and mycobactericidal protection,# while
ensuring that HLD is performed accurately and consistently. trophon
technology is able to eliminate an extended range of clinically
relevant pathogens, including multi-drug resistant bacteria,
blood-borne viruses, and sexually transmitted pathogens.# trophon
technology delivers HLD to meet accreditation requirements and
support best practice patient care.
Furthermore, the recently launched Nanosonics AuditPro™ offers
infection preventionists and quality managers an opportunity to
improve and standardize ultrasound probe infection control
compliance to support the management of healthcare-associated
infection (HAI) risk. The mobile application is designed to be used
at the ultrasound console, seamlessly providing best practice
infection control education as part of the clinical workflow, and
standardizing infection control practices to meet accreditation
requirements.
“Nanosonics’ solid momentum in North America underscores the
growing demand for our comprehensive HLD and workflow management
solutions, enabling infection preventionists and caregivers the
ability to consistently support optimal patient care and
standardize infection control compliance,” said Shaw.
In related news, Nanosonics will host a symposium titled,
“Strategies to Inform Device Reprocessing Policy Toward Patient
Safety” at the annual meeting of the Association for Professionals
in Infection Control and Epidemiology (APIC) in Indianapolis, on
June 13. The company will also showcase its suite of infection
prevention solutions at the meeting, June 13-15 in booth #1456.
About Nanosonics
Nanosonics (ASX:NAN) is a leading medical technology company
headquartered in Sydney, Australia, with its North American
operations based in Indianapolis. Founded in 2001, the company is
one of Australia’s largest medical technology companies and a
recognized leader in its sector of the global infection control
market. For more information, visit www.nanosonics.us.
*The trophon:registered: family includes trophon:registered: EPR
and trophon:registered:2 devices which share the same core
technology of 'sonically activated' hydrogen peroxide.
#Internal testing according to guidelines from FDA (Reprocessing
Medical Devices in Health Care Settings : Validation Methods and
Labelling ,2015) and AAMI(TIR30:2011. A compendium of processes,
materials, test methods and acceptance criteria for cleaning
reusable medical devices).
____________________________________________________
1 Buescher, D. L., et al. (2016). Disinfection of transvaginal
ultrasound probes in a clinical setting: comparative performance of
automated and manual reprocessing methods. Ultrasound Obstet
Gynecol 47(5): 646-651. 2 Oide, S., et al. (2019). Incidence of
residual bacterial contamination of transvaginal ultrasound probes.
J Med Ultrason 46(4): 475-479. 3 Keys, M., et al. (2015). Efforts
to Attenuate the Spread of Infection (EASI): a prospective,
observational multicentre survey of ultrasound equipment in
Australian emergency departments and intensive care units. Crit
Care Resusc 17(1): 43-46 4 Leroy S, et al. J Hosp Infect
2013;83(2): 99-106. 5 M'Zali, F., et al. 2014. PLoS One 9(4):
e93368
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220608005044/en/
Amy Cook amy@amcpublicrelations.net
Nuveen New York Quality ... (NYSE:NAN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Nuveen New York Quality ... (NYSE:NAN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024